$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUEPRNewsWire • 02/21/25
bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech ExecsAccesswire • 02/21/25
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public ShareholdersBusiness Wire • 02/21/25
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to ShareholdersBusiness Wire • 02/21/25
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalBusiness Wire • 02/21/25
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsCNBC • 02/18/25
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 12/08/24
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb LevelsBusiness Wire • 12/07/24
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access ModelBusiness Wire • 12/04/24
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 BuysSeeking Alpha • 11/20/24
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding OptionsBenzinga • 11/15/24
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceBusiness Wire • 11/14/24
After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)Zacks Investment Research • 11/08/24
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results CallBusiness Wire • 11/06/24
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 11/05/24